186 related articles for article (PubMed ID: 32087684)
1. Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis.
Riccio E; Sabbatini M; Capuano I; Pellegrino AM; Petruzzelli LA; Pisani A
BMC Nephrol; 2020 Feb; 21(1):57. PubMed ID: 32087684
[TBL] [Abstract][Full Text] [Related]
2. Budget Impact Analysis of Oral Fisiogen Ferro Forte
Darbà J; Ascanio M
Clin Drug Investig; 2018 Sep; 38(9):801-811. PubMed ID: 29934762
[TBL] [Abstract][Full Text] [Related]
3. An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic.
Wilson PD; Hutchings A; Jeans A; Macdougall IC
J Med Econ; 2013; 16(1):108-14. PubMed ID: 22989163
[TBL] [Abstract][Full Text] [Related]
4. Oral high-dose sucrosomial iron vs intravenous iron in sideropenic anemia patients intolerant/refractory to iron sulfate: a multicentric randomized study.
Giordano G; Napolitano M; Di Battista V; Lucchesi A
Ann Hematol; 2021 Sep; 100(9):2173-2179. PubMed ID: 33263170
[TBL] [Abstract][Full Text] [Related]
5. Novel Oral Iron Therapies for Iron Deficiency Anemia in Chronic Kidney Disease.
Pergola PE; Fishbane S; Ganz T
Adv Chronic Kidney Dis; 2019 Jul; 26(4):272-291. PubMed ID: 31477258
[TBL] [Abstract][Full Text] [Related]
6. The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale.
Macdougall IC; Bock A; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Cushway T; Roger SD;
Nephrol Dial Transplant; 2014 Apr; 29(4):843-50. PubMed ID: 24170814
[TBL] [Abstract][Full Text] [Related]
7. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial.
Pisani A; Riccio E; Sabbatini M; Andreucci M; Del Rio A; Visciano B
Nephrol Dial Transplant; 2015 Apr; 30(4):645-52. PubMed ID: 25395392
[TBL] [Abstract][Full Text] [Related]
8. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
Pollock RF; Muduma G
J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
[No Abstract] [Full Text] [Related]
9. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Nolen JG; Roger SD;
Nephrol Dial Transplant; 2014 Nov; 29(11):2075-84. PubMed ID: 24891437
[TBL] [Abstract][Full Text] [Related]
10. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
Ziedan A; Bhandari S
Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
[TBL] [Abstract][Full Text] [Related]
11. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia.
Calvet X; Gené E; ÀngelRuíz M; Figuerola A; Villoria A; Cucala M; Mearin F; Delgado S; Calleja JL
Technol Health Care; 2016; 24(1):111-20. PubMed ID: 26409561
[TBL] [Abstract][Full Text] [Related]
12. A fast-track anaemia clinic in the Emergency Department: cost-analysis of intravenous iron administration for treating iron-deficiency anaemia.
Quintana-Díaz M; Muñoz-Romo R; Gómez-Ramírez S; Pavía J; Borobia AM; García-Erce JA; Muñoz M
Blood Transfus; 2017 Sep; 15(5):438-446. PubMed ID: 28151394
[TBL] [Abstract][Full Text] [Related]
13. NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease.
Kalra PA; Bhandari S; Spyridon M; Davison R; Lawman S; Mikhail A; Reaich D; Pritchard N; McCafferty K; Moore J
BMC Nephrol; 2020 Dec; 21(1):539. PubMed ID: 33302891
[TBL] [Abstract][Full Text] [Related]
14. Financial impact of intravenous iron treatments on the management of anaemia inpatients: a 1 year observational study.
Delpeuch A; Ruivard M; Abergel A; Aumaitre O; Boisgard S; Bagel S; Sautou V
Int J Clin Pharm; 2018 Jun; 40(3):686-692. PubMed ID: 29520555
[TBL] [Abstract][Full Text] [Related]
15. Effects of a multifaceted intervention to promote the use of intravenous iron sucrose complex instead of ferric carboxymaltose in patients admitted for more than 24 h.
Touchard J; Perrin G; Berdot S; Pouchot J; Loustalot MC; Sabatier B
Eur J Clin Pharmacol; 2021 Feb; 77(2):189-195. PubMed ID: 32926203
[TBL] [Abstract][Full Text] [Related]
16. Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency in Adults.
Khoury A; Pagan KA; Farland MZ
Ann Pharmacother; 2021 Feb; 55(2):222-229. PubMed ID: 32633548
[TBL] [Abstract][Full Text] [Related]
17. Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial.
Roger SD; Gaillard CA; Bock AH; Carrera F; Eckardt KU; Van Wyck DB; Cronin M; Meier Y; Larroque S; Macdougall IC;
Nephrol Dial Transplant; 2017 Sep; 32(9):1530-1539. PubMed ID: 28339831
[TBL] [Abstract][Full Text] [Related]
18. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
[TBL] [Abstract][Full Text] [Related]
19. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.
Mafodda A; Giuffrida D; Prestifilippo A; Azzarello D; Giannicola R; Mare M; Maisano R
Support Care Cancer; 2017 Sep; 25(9):2779-2786. PubMed ID: 28391437
[TBL] [Abstract][Full Text] [Related]
20. Creative iron management--a practical guide.
Jenkins K
J Ren Care; 2009 Dec; 35 Suppl 2():32-5. PubMed ID: 19891684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]